PURPOSE: Short chain @entity9932 induce @entity5 cell apoptosis in preclinical models. Limited therapeutic options for @entity1 with @entity0 prompted the testing of these @entity13740 in @entity1 with this disease. @entity1 AND METHODS: Twenty-five @entity1 with refractory, @entity0 were treated twice a day with a 1% mixture of topical C2 and C6 @entity9932 administered in a 1:1 ratio. For the first 8 weeks, @entity1 were not allowed to receive other antineoplastic therapy. In addition to @entity5 status and @entity137 assessment throughout the trial, skin biopsies for evidence of apoptosis and quality of life questionnaires (FACT-BR) were completed at baseline and 1 month. RESULTS: Only one @entity1 manifested a partial response with topical @entity9932 , yielding a response rate of 4% (90% confidence interval 0, 17.6%). Median cutaneous progression-free survival was 2 months. The topical @entity9932 were also well tolerated, with no grade 3 or 4 @entity137 reported. None of the six @entity1 who underwent serial skin biopsies showed @entity5 cell apoptosis morphologically or by the modified TUNEL assay. CONCLUSION: To our knowledge, this trial is one of the first clinical investigations of short chain @entity9932 . This trial's results are not promising enough to merit further study of @entity9932 in the manner prescribed.

A phase II study of topical @entity9932 for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity0 :: ('MESH:D001943', 'Disease') :: ['cutaneous breast cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'increased tumor'] @entity13740 :: ('MESH:D013107', 'Chemical') :: ['sphingolipids'] @entity9932 :: ('MESH:D002518', 'Chemical') :: ['ceramides']
@entity0 :: (MESH:D001943,Disease) :: ['cutaneous breast cancer']
